beta-amyloid 40 (Aβ40) antibody and antigen (Recombinant protein)
Diagnostic beta-amyloid 40 (Aβ40) antibodies (anti-beta-amyloid 40, anti-Aβ40) and antigens (recombinant beta-amyloid 40 (Aβ40) protein) for Neurodegenerative diseases Aβ40 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-h-Aβ40-Ag01 | Recombinant human APP/Aβ40/A4/AD1 Protein | 3090 |
GMP-h-Aβ40-Ab01 | Anti-human APP/Aβ40/A4/AD1 mouse monoclonal antibody (mAb) | 1953 |
GMP-h-Aβ40-Ab02 | Anti-human APP/Aβ40/A4/AD1 mouse monoclonal antibody (mAb) | 1953 |
GMP-h-Aβ40-Ab03 | Anti-human APP/Aβ40/A4/AD1 human monoclonal antibody (mAb) | 1953 |
GMP-h-Aβ40-Ab04 | Anti-human APP/Aβ40/A4/AD1 human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-h-Aβ40-Ag01 |
Product Name | Recombinant human APP/Aβ40/A4/AD1 Protein |
Target/Biomarker | beta-amyloid 40 (Aβ40) |
Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4 |
Expression platform | mammalian |
Isotypes | Recombinant Antigen |
Bioactivity validation | beta-amyloid 40 (Aβ40) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ40 level test of Neurodegenerative diseases (Alzheimer Disease (AD)) and related syndrome evaluation. |
Tag | His |
Products description | Recombinant human APP/Aβ40/A4/AD1 Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-h-Aβ40-Ab01, GMP-h-Aβ40-Ab02 |
Product Name | Anti-human APP/Aβ40/A4/AD1 mouse monoclonal antibody (mAb) |
Target/Biomarker | beta-amyloid 40 (Aβ40) |
Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4 |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | beta-amyloid 40 (Aβ40) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ40 level test of Neurodegenerative diseases (Alzheimer Disease (AD)) and related syndrome evaluation. |
Tag | mFc |
Products description | Anti-human APP/Aβ40/A4/AD1 mouse monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-h-Aβ40-Ab03, GMP-h-Aβ40-Ab04 |
Product Name | Anti-human APP/Aβ40/A4/AD1 human monoclonal antibody (mAb) |
Target/Biomarker | beta-amyloid 40 (Aβ40) |
Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4 |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | beta-amyloid 40 (Aβ40) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ40 level test of Neurodegenerative diseases (Alzheimer Disease (AD)) and related syndrome evaluation. |
Tag | hFc |
Products description | Anti-human APP/Aβ40/A4/AD1 human monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Good performance of GeneMedi's Aβ40/Aβ42 antibodies in ELISA and CLIA Validation
The high-performance Aβ40 and Aβ42 antibody raw materials developed by GeneMedi have the advantages of good specificity and high sensitivity, and are the preferred raw materials for the development of in vitro diagnostics reagents for Alzheimer's disease.
In direct ELISA analysis, GMP-h-Aβ40-Ab01 and GMP-h-Aβ42-Ab01 can Recognizes Aβ40 or Aβ42 with high specificity. GMP-h-Aβ42-Ab02 has cross-reactivity with both Aβ40 and Aβ42.
In CLIA verification, the antibody pair (Capture: GMP-h-Aβ40-Ab01 , Detect: GMP-h-Aβ42-Ab02 ) can detect the GMP-h-Aβ40-Ag01, and the antibody pair (Capture: GMP-h-Aβ42-Ab02 , Detect: GMP-h-Aβ42-Ab01 ) can detect the GMP-h-Aβ42-Ag01. Beta-amyloid(1-42) antibodies (GMP-h-Aβ42-Ab02 and GMP-h-Aβ42-Ab01) established a standard curve, and the detection range of Aβ42 was 100-1700 pg/mL.
Figure 1: Good performance of GeneMedi's Aβ40/Aβ42 antibodies in ELISA and CLIA Validation
A. GMP-h-Aβ40-Ab01 and GMP-h-Aβ42-Ab02 can bind GMP-h-Aβ40-Ag01, while GMP-h-Aβ42-Ab01 can not bind the Aβ40 antigen in direct ELISA.
B. GMP-h-Aβ42-Ab01 and GMP-h-Aβ42-Ab02 can bind GMP-h-Aβ42-Ag01, while GMP-h-Aβ40-Ab01 can not bind the Aβ42 antigen in direct ELISA.
C. CLIA verification data of the antibody pair (Capture: GMP-h-Aβ40-Ab01 , Detect: GMP-h-Aβ42-Ab02 ) to detect the GMP-h-Aβ40-Ag01.
D. CLIA verification data of the antibody pair (Capture: GMP-h-Aβ42-Ab02 , Detect: GMP-h-Aβ42-Ab01 ) to detect the GMP-h-Aβ42-Ag01.
Click to get more Data / Case study about the product.
Target/Biomarker information
Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. Low plasma Aβ42/40 was associated with more pronounced decline in cognitive function (measured by multiple outcomes) over time. Findings suggest that plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an alternative to more complex and expensive measures, such as positron emission tomography imaging or cerebrospinal fluid measurement.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.